Zane was just 15 months old when his parents noticed something wasn’t right. His eyes, legs and belly were very swollen. At first, it seemed like allergies. As soon as the pediatrician saw Zane, he ...

Focal segmental glomerulosclerosis (FSGS) still lacks an FDA-approved therapy, but late-breaking post hoc results from the phase III DUPLEX trial -- presented at the National Kidney Foundation Spring ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Treatment for 72.1% of patients involved in-center ...

A spectrum of nondiabetic kidney diseases is associated with APOL1 high-risk genotypes (G1G1, G1G2, and G2G2), but the M1 variant has been understudied.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the launch of a new awareness campaign, “Play It Forward,” to bring hope and encouragement to the focal segmental ...

The most important message is that FSGS is a lesion and not a disease. The finding of an FSGS lesion is the start of an exploratory process leading to a diagnosis and not an end in itself. We propose ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often and more quickly on sparsentan (Filspari) than irbesartan (Avapro), secondary ...

FSGS is characterized by proteinuria, where protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney. Once in the urine, protein is considered to be toxic to ...

What is your opinion about using preemptive plasma exchange before living-related kidney transplantation (mother) in a 12-year-old boy with end-stage renal failure secondary to focal segmental ...

M any cases of kidney disease in the United States are linked to other serious medical conditions like high blood pressure or diabetes. But there are also forms of kidney disease that strike without ...

A drug being developed by Boehringer Ingelheim for COVID-19 and reinvented as a potential therapy for kidney disease has now hit the mark in a phase 2 trial. TRPC6 inhibitor apecotrep (BI 764198), ...